STOCK TITAN

BioCardia (BCDA) 10-K Filings

BCDA NASDAQ

Here are the 10-K annual reports from BioCardia, Inc. (BCDA) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 10-K covers the audited annual report, with the full financial statements, so if you follow BCDA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BCDA filings page.

Form 10-K
Rhea-AI Summary

BioCardia, Inc. provides an in-depth overview of its clinical-stage cardiovascular and pulmonary cell therapy business. The company is advancing the autologous CardiAMP platform for ischemic heart failure with reduced ejection fraction and chronic myocardial ischemia, and the allogeneic CardiALLO and PulmALLO MSC platforms for heart failure and acute respiratory distress syndrome.

The CardiAMP heart failure program has completed a Phase III trial that did not meet its primary endpoint but showed clinically meaningful and statistically significant echocardiographic benefits in a prespecified high-risk subgroup, and is now supported by a confirmatory CardiAMP HF II trial with Centers for Medicare & Medicaid Services coverage. CardiAMP has FDA Breakthrough Device Designation, and BioCardia is pursuing regulatory pathways in the United States and Japan, while also seeking separate approval of its Helix transendocardial delivery system and leveraging CMS-backed pivotal trials to reduce development costs.